The company plans to use the funding to take the drug to the point at which it can file an Investigational New Drug application with federal regulators, CEO Lane Brostrom said. He expects that to happen sometime next year.
The funding could also help finance Phase 1 trials of the drug, Brostrom said.
Cytometix has collaborated with the Medical College of Wisconsin in developing the drug. David Harder, Cytometix’s chief scientific consultant, is the former director of the Medical College of Wisconsin’s Cardiovascular Center.
For competitive reasons, Brostrom was reluctant to provide much detail of Cytometix’s plans. “I don’t want anybody getting too curious,” he said.
Cytometix is also developing a drug to treat asthma, but it’s about a year behind the pain drug in the development life cycle, Brostrom said.
The fundraise was sourced from angel investors, with the date of the first sale on July 2. The minimum investment accepted was $12,500, according to the regulatory document.
In addition to private funding, Cytometix has been financed through an SBIR grant from the National Institutes of Health.
The company was founded in 2004, according to the Milwaukee Journal-Sentinel.